Results
Anthem Biosciences Q2 PAT Up 21.9% YoY to ₹2,115 Mn
Anthem Biosciences reported Q2FY27 consolidated revenue of ₹5,940 Mn, a 7.9% YoY growth, driven by strong CRDMO performance.
EBITDA surged 24.1% YoY to ₹3,304 Mn with margins expanding 610 bps to 50.6
